Pre-IND meeting is a procedural step with binary outcome risk; no revenue or catalyst date until IND clearance and trial initiation. Monitor FDA feedback post-June meeting and any subsequent financing needs given going concern warning. Stock may see speculative volatility but lacks fundamental catalyst until clinical data emerges.
Price Chart
Executive Summary
NewcelX announced submission of a Pre-IND briefing package to the FDA for NCEL-101 (stem-cell-derived islet therapy) combined with tegoprubart for type 1 diabetes, with a Type B pre-IND meeting scheduled for late June 2026. This is an early-stage regulatory milestone for a clinical-stage company with a $17M market cap, but no financial data, guidance, or near-term revenue catalyst is provided.
Key Facts
- Pre-IND briefing package submitted to FDA for NCEL-101 + tegoprubart combination in type 1 diabetes.
- Type B pre-IND meeting scheduled for last week of June 2026.
- NCEL-101 is an enriched stem cell-derived islet product candidate; tegoprubart is an investigational anti-CD40L antibody from Eledon Pharmaceuticals (ELDN).
- Supported by 12-patient investigator-initiated study at University of Chicago Medicine showing preserved islet function with tegoprubart.
- Tegoprubart has been used in >100 transplant recipients across multiple FDA-cleared INDs.
- NewcelX is a clinical-stage regenerative medicine company with no approved products or disclosed revenue.
- Market cap is $17M; analyst consensus is 0% bullish (3 Hold, 1 Sell, 2 Strong Sell).
- Forward-looking statements note substantial doubt about going concern and Nasdaq listing compliance.
Financial Impact
No financial figures disclosed; pre-IND milestone with no revenue or cost data.
Risk Factors
- Going concern risk noted in forward-looking statements — company may need dilutive financing.
- Nasdaq listing compliance risk — potential delisting if market cap or bid price issues persist.
- Pre-IND meeting outcome uncertain; FDA may require additional preclinical data delaying timeline.
- No approved products or revenue; clinical-stage biotech with binary event risk.
- Analyst consensus heavily bearish (0% bullish) with 3 Hold, 3 Sell/Strong Sell.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301840 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | EFFECT | $2.86 $3.08 | ▼ −7.52% | ▼ −8.19% | $2.55 (+10.84%) |
Sep 18, 2026 5w ago | 6-K | $2.97 $2.92 | ▲ +1.68% | ▲ +0.66% | $2.55 (+14.14%) |
Aug 27, 2026 8w ago | EFFECT | $3.42 $3.35 | ▲ +2.05% | ▲ +1.28% | $2.55 (+25.44%) |
Jul 31, 2026 12w ago | 6-K | $3.49 $3.31 | ▼ −5.16% | ▼ −8.67% | $2.55 (−26.93%) |
Jul 15, 2026 14w ago | 6-K | $3.93 $3.65 | ▼ −7.12% | ▼ −6.14% | $2.55 (−35.11%) |
Jul 8, 2026 15w ago | 6-K | $4.23 $3.98 | ▼ −5.91% | ▼ −6.77% | $2.55 (−39.72%) |
Jul 1, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 30, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 18, 2026 18w ago | EFFECT | $3.31 $3.55 | ▼ −7.25% | ▼ −8.92% | $2.55 (+22.96%) |
Jun 5, 2026 20w ago | 6-K | $3.24 $3.20 | ▼ −1.23% | ▼ −3.35% | $2.55 (−21.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers